A meta-analysis from 2022 looking at 10 RCTs which confirmed the lower risk of OHSS using a GnRH-antagonist protocol, but a lower retrieved oocyte number. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.